GlobeNewswire: PALISADE BIO, INC. Contains the last 10 of 292 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:40:43ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853120/0/en/Palisade-Bio-Reports-Year-End-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=28921Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update2024-03-27T12:00:00Z<![CDATA[– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end]]>https://www.globenewswire.com/news-release/2024/02/15/2829979/0/en/Palisade-Bio-to-Present-at-Digestive-Disease-Week-DDW-2024.html?f=22&fvtc=4&fvtv=28921Palisade Bio to Present at Digestive Disease Week (DDW) 20242024-02-15T13:35:00Z<![CDATA[Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024.]]>https://www.globenewswire.com/news-release/2024/02/13/2828263/0/en/Palisade-Bio-Provides-Corporate-Update-and-Reiterates-Guidance.html?f=22&fvtc=4&fvtv=28921Palisade Bio Provides Corporate Update and Reiterates Guidance2024-02-13T13:35:00Z<![CDATA[– Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision]]>https://www.globenewswire.com/news-release/2024/02/08/2826400/0/en/Correction-Notice-of-Palisade-Bio-s-Press-Release-Announcing-the-Appointment-of-Clinical-Advisory-Board-Members.html?f=22&fvtc=4&fvtv=28921Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members2024-02-08T19:40:00Z<![CDATA[Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB).]]>https://www.globenewswire.com/news-release/2024/02/08/2825996/0/en/Palisade-Bio-Announces-Formation-of-Clinical-Advisory-Board-with-Appointments-of-Preeminent-Key-Opinion-Leaders.html?f=22&fvtc=4&fvtv=28921Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders2024-02-08T13:05:00Z<![CDATA[Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). Drs. Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.]]>Bruce Sands MD, MSPalisade Bio, Inc.Florian Rieder, MDPalisade Bio, Inc.https://www.globenewswire.com/news-release/2024/01/30/2820114/0/en/Palisade-Bio-Announces-Exercise-of-Previously-Issued-Warrants-for-2-5-Million.html?f=22&fvtc=4&fvtv=28921Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million2024-01-30T14:25:00Z<![CDATA[Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 3,413,286 shares of common stock. The Existing Warrants had initial exercise prices of $35.525, $2.375, and 2.64, respectively, and were issued by the Company on May 10, 2022, January 4, 2023, and April 5, 2023, respectively, with each exercise occurring at a reduced exercise price of $0.7313 per share.]]>https://www.globenewswire.com/news-release/2024/01/29/2818876/0/en/Palisade-Bio-Announces-Positive-Preclinical-Data-of-Lead-Program-PALI-2108-at-the-2024-Crohn-s-Colitis-Congress.html?f=22&fvtc=4&fvtv=28921Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress2024-01-29T13:05:00Z<![CDATA[– Preclinical data demonstrated PALI-2108 to be safe and well tolerated]]>https://www.globenewswire.com/news-release/2024/01/09/2806236/0/en/Palisade-Bio-Selected-for-Poster-Presentation-at-the-2024-Crohn-s-Colitis-Congress.html?f=22&fvtc=4&fvtv=28921Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress2024-01-09T13:00:00Z<![CDATA[Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held January 25-27, 2024 in Las Vegas, NV.]]>https://www.globenewswire.com/news-release/2023/12/28/2801689/0/en/Palisade-Bio-Announces-Receipt-of-Second-Milestone-Payment-from-the-US-Crohn-s-and-Colitis-Foundation-for-Development-of-PALI-2108.html?f=22&fvtc=4&fvtv=28921Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-21082023-12-28T13:00:00Z<![CDATA[- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s and Colitis Foundation]]>https://www.globenewswire.com/news-release/2023/11/10/2778291/0/en/Palisade-Bio-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Outlook.html?f=22&fvtc=4&fvtv=28921Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook2023-11-10T13:05:00Z<![CDATA[– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market]]>